Recurrent and Metastatic Head and Neck Cancer

Geoffrey Neuner, MD

Introduction

It is an understatement to say head and neck cancer is a challenging disease for patients, caregivers and clinicians. Curative treatment consists of either surgery, radiation or both, often combined with cytotoxic chemotherapy. The individual treatments for head and neck cancer have improved somewhat over the past 30 years with the development of minimally invasive surgical techniques, organ sparing radiation techniques, better side effect control for chemotherapy, and newer systemic agents such as immunotherapy. However, the overall backbone of curative treatment has changed little in that time period and is associated with significant toxicity. As survivors of head and neck cancer understand, once diagnosed there can be a permanency of the disease or its sequelae in the lives of patients and their caregivers. Although improvements in outcomes are occurring in the oropharyngeal subgroup of patients, this improvement is mainly related to the distinct biological differences in the origin of this disease as well as the generally better health of these patients. Even still, there is a significant risk of recurrence in both oropharyngeal patients with advanced disease and in patients with oral, laryngeal, sinus, hypopharyngeal, or nasopharyngeal cancer. This can consist of recurrence of disease in the site of origin (local), the neck (regional recurrence), as well as in organs distant from the original cancer (distant metastases), or any and all of these areas. A lack of studies guiding treatment in these situations, called “salvage treatment,” requires patients and clinicians to be astute in the nature of the recurrence, probable outcomes, and risks of further treatment toxicity. This article will discuss some of the most common recurrence scenarios encountered in head and neck cancer patients.

Local and Regional Recurrence of Disease

Unfortunately, there is no subsite in the head and neck that is associated with a 100% cure rate after local therapy. After surgery, radiation, or chemotherapy combined with radiation (chemoradiation) are well established treatment regimens used to reduce the risk of recurrence, but up to 30% of patients recur nonetheless. The need for salvage treatment is not just limited to patients treated primarily by surgery. In trials and retrospective reports, 10-15% of patients undergoing curative radiation for very small larynx cancers will require removal of the larynx afterward, either for return of the cancer or for a second tumor that arises years later. Salvage treatment after initial curative treatment can be challenging, as anatomy may have already been altered by initial surgery, radiation, or both, and further treatment may severely limit functional outcomes.

Salvage treatment of head neck cancer is a very specialized field and requires input from experienced clinicians, including head and neck surgeons, radiation oncologists and medical oncologists who specialize in head and neck cancer. As head and neck cancer is actually a rare disease, specialization in the treatment of recurrence is something that is best undertaken at large referral centers that possess the expertise to advise patients accurately and manage both the salvage treatment and potential sequelae thereof.

Treatment is often tailored to very individualized situations, and the salvage treatment recommended depends on the initial therapy that was delivered, site of disease, patient health, and even the location within the organ. For example, a well lateralized recurrent oral tongue cancer may be excised, but another recurrent oral tongue cancer of the same size in the middle of the tongue may require complete removal of the tongue. In retrospective reports, patients who are able to undergo surgery as a salvage local treatment tend to fare better. Although this may point to the biology of the recurrent cancer itself, if patients are able to undergo surgery, it is generally preferred because of this data. Recurrent cancer, in general, is a reason to receive radiation. In patients with a previous history of radiation treated with salvage surgery, there is very little data to guide treatment.
RECURRENT HNC continued from page 1

recommendations, though one phase 3 clinical trial has compared immediate post-operative chemo reirradiation to observation. Although local control of the cancer was improved with postoperative therapy, life span was no different and severe adverse events were higher in the group that received immediate therapy. This is thought to be due to many reasons, including the multiple medical problems these patients have at this point in their lives as well as the high risk of the cancer to have spread to other organs after the application of salvage surgery.

Regional recurrence of disease describes regrowth of cancer in the lymph nodes of the neck, one of the primary routes of spread of head and neck cancer. In the event that a patient hasn’t had radiation, regional recurrence can be managed with chemoradiation or surgery. However, if radiation was given before, regional recurrences are best managed with surgery, when possible. Reirradiation or chemo reirradiation can be given after surgery, but again there are risks given the neck muscles, skin, blood vessels, nerves, and spinal cord have all been radiated, and could sustain potential injury from the second dose of radiation. One radiation option performed in very specialized centers with experience in this area is brachytherapy. Meaning “near-therapy,” it consists of the placement of radioactive sources right next to the area at risk for recurrence. This potentially limits the amount of radiation given to the already treated neck, while delivering a substantial dose of radiation right to the tissues at risk.

For patients who are unable to undergo salvage surgery, re-irradiation or chemo re-irradiation are potential options. Unfortunately, long term control of the recurrent cancer as well as survival of these patients are poor, for the same reasons listed above; poor patient health, further local/regional recurrence, and a high risk of spread to other organs. In addition, re-irradiation as a treatment modality is often limited because it is considered unsafe to deliver another full dose of radiation, and the therapeutic benefit doesn’t justify further treatment of sites that may have be at risk for spread. In addition, if the patient has received radiation before, the blood supply to the tissue will often be poorer than it was before receiving radiation, and this can cause radiation to be less effective, as radiation at low doses requires oxygen in the tissue to help facilitate the destruction of tumor DNA.

Radiation is typically given in small daily doses for 6 weeks in the recurrent setting. Radiation oncologists can lower the dose per treatment and give two treatments per day, which should biologically make the radiation easier on the normal tissues surrounding the tumor. This is important, because patients who receive radiation for a second time have a small risk of severe life threatening tissue damage. A newer form of treatment called stereotactic body radiotherapy is delivered with high doses per treatment over 1 to 2 weeks, which biologically may overcome some of the issues with tissue oxygenation. These radiation regimens have not been compared and any one of them may be more appropriate based on the tumor location, patient prognosis, patient health, and patient desires. Finally, there are situations where proton therapy may have a therapeutic advantage, given its ability to deposit less dose in the surrounding normal tissues.

The poor outcomes with reirradiation are reflected in the National Comprehensive Cancer Network Guidelines (www.nccn.org).
For those able to receive treatment for metastatic spread, treatment again consists mainly of systemic therapies: cytotoxic chemotherapy, cytotoxic chemotherapy combined with cetuximab, or immunotherapy. For those who have a significant burden of symptoms but are still able to receive systemic therapy, single agent rather than combination therapy is recommended. For those with a minimal burden of symptoms and a good ability to participate in the daily activities of life, multi-agent systemic therapy is the treatment of choice after clinical trial enrollment, and can consist of the agents discussed in the local/regional recurrence setting above. Usually, if the cancer becomes resistant to the current regimen, the patient is switched to new regimens until the patient is unable to tolerate further therapy or the cancer grows beyond the control of any therapy. At that time, palliative care services are essential for symptom control, end of life planning, and psychological counseling.

Oligometastatic disease

Over the past 40 years, it has become more and more apparent that, regardless of cancer, there are patients who develop limited metastatic spread of cancer who may be cured by local therapy to the site of spread. Limited metastatic spread is called “oligometastatic” disease, and classically has been defined as having 1-5 metastases. The curative potential of patients with oligometastatic disease was first shown in patients with colorectal cancer with limited spread to the liver; up to 25% of these patients were cured with resection of the primary tumor and metastases in the liver. This was an important finding, because we now know that the metastatic tumors themselves can spread to other areas, not just the primary tumor. Over the years, reports of patients with other cancers with limited metastatic spread, who do well with local therapy to the site of spread, have emerged, including patients with breast cancer, prostate cancer, sarcoma, and even lung cancer. More recently, studies have shown that patients with limited metastatic head and neck cancers, particularly from the oropharynx, may have prolonged survivals after treatment of their sites of limited metastatic disease.

Treatment for oligometastatic disease can be surgery or radiation, usually SBRT. The latter is used because the sites of...
spread have usually not been radiated before, and are often in organs which can tolerate a large, destructive dose of radiation to a small part of the organ. These treatments can be delivered in as little as one treatment of radiation, and are associated with control rates of upwards of 90%. In cases where disease responds to systemic therapy and comes back in limited spots (oligorecurrent), or if most of the disease disappears except for a few spots (oligopersistent), SBRT can be used to ablate the recurrent or persistent areas in these patients as well. It has been difficult to accrue patients to clinical trials testing the hypothesis behind this treatment, as more and more clinicians believe it to be unfair to withhold such treatment in these situations.

Conclusions
The treatment of recurrent disease is an extremely difficult and nuanced situation for the head and neck patient. Local/regional recurrence is likely best treated with surgery. The application of repeat courses of chemoradiation afterward have to be considered carefully. Repeat courses of chemoradiation as a definitive treatment can be effective in a minority of patients, but are usually mostly palliative. In the patient not eligible for surgery, clinical trial enrollment is encouraged. Although systemic therapy for local/regional recurrence or distant spread were associated with poor survival for decades, recent improvements including immunotherapy are changing the landscape and allowing for more multimodality management, including the aggressive treatment of oligometastatic, oligorecurrent and oligopersistent disease.

Editor’s Note: Geoffrey Neuner is a radiation oncologist in Baltimore. He completed his residency in 2011 at the University of Maryland Medical Center after graduating from Eastern Virginia Medical School in 2006. He currently is a radiation oncologist with Radiation Oncology Healthcare, PA. Dr. Neuner is the main consulting radiation oncologist for the Milton J. Dance, Jr. Head and Neck Center, a private head and neck cancer treatment and rehabilitation center. He has a diverse private practice, but concentrates on the treatment of patients with head and neck, breast and prostate cancers.
Support for People with Oral and Head and Neck Cancer, Inc. is grateful for the generosity of its contributors. Thanks to their support, SPOHNC is able to maintain and extend its programs of education and support to cancer survivors, their families and friends. With sincere appreciation to all.

VISIONARY CIRCLE
Contributions of $15,000+
- Bristol-Myers Squibb
- Iovance
- MedImmune/AstraZeneca
- Merck

BENEFACTORS
Contributions of $1,000+
- Anonymous, Walter & Irene Boehmeler
- Lawrence & Gina DiGiovanna
- Raymond D. Gambale
- Dennis S. Holz, James Prange, Aline Quester, Gail Simmons
- Borden & Cynthia Taylor
- Ronald and Sandra Walker

SPOHNC’S VISIONARY CIRCLE
AstraZeneca Pharmaceuticals is a global biopharmaceutical business that pushes the boundaries of science to deliver life changing medicines.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL)

Merck discovers, develops and provides innovative products and services that save and improve lives around the world.

PATRONS
Contributions of $500+
- Charles Banta, Linda & Robert Culpepper, John & Roberta Davis, Mr. & Mrs. Gillaspie-Hargas, Robert Kreps, Mark S. Persky, MD, Susan Quade O.D., Charles & Barbara Raab, Carl Reimderes, James J. Scubba, DMD, PhD, Douglas E. Simms, The Social Ministry Committee, Scott Stone, Daniel M. Tanenbaum

SPONSORS
Contributions of $100+
DONORS
Contributions of $50+


BOOSTERS
Contributions of $25+

Swedish Meatballs (from Volume Two)

1.5 lb. ground beef  
¾ c. dried breadcrumbs  
1 egg  
¼ c. onions, chopped finely  
2 Tbsp. dried parsley  
1/14 tsp. salt  
¼ tsp. paprika  
1/8 tsp. pepper  
1 tsp Worcestershire sauce  
½ c milk  
1 can beef bouillon  
Cooking sherry

Saute chopped onions in butter or margarine. Combine with all other ingredients except bouillon and cooking sherry and form into small cocktail sized meatballs. Simmer meatballs, covered, in a pan with whole can bouillon, seasoned with a touch of cooking sherry. Serves 6. 336 calories/serving.

~ Nyra T., NY
SPOHNC Founder, Survivor and President Emeritus Nancy Leupold

SPOHNC is honoring a very special birthday– one that holds deep meaning for all of us here at SPOHNC.

March 21st of this year marked a significant birthday for our Founder, Survivor and President Emeritus, Nancy Leupold. We’re not giving away her secret, but we want to wish this visionary, and remarkable woman a very, very Happy Birthday!

Nearly 30 years ago, Nancy, began her journey with oral, head and neck cancer, and her quest to help and provide hope, healing and support for those who would travel a journey similar to her own.

An amazing woman with a vision created Support for People with Oral and Head and Neck Cancer (SPOHNC) beginning with one support group, formed on Long Island, and an organization that started in her home, to the now more than 120 support groups across the United States, and a matching program that is more than 200 strong. Nancy was determined to keep moving forward and creating new programs and materials that would help future newly diagnosed patients and their families as they looked ahead.

Fast forward to 2019, SPOHNC now has a large social media presence, along with 2 cookbooks, 2 print publications for newly diagnosed patients, a newsletter published 8 times per year and a Product Directory, as well as a newly redesigned website. SPOHNC continues to grow and thrive as we uphold the mission that Nancy created.

Nancy has been the driving force behind SPOHNC and our programs and services since the beginning. Her passion and dedication will always mean so much to those who have benefited from the support and camaraderie offered through SPOHNC.

Pictured here during recent special family time where everyone celebrated the most important occasion, it seems our Founder is enjoying a new addition to the family. Congratulations to all!!!

Happy Birthday to someone who has taught us the value of support, friendship, living life to the fullest and appreciating every single day. With gratitude, appreciation and respect for being such an inspiration to all newly diagnosed patients, survivors and their families…

We hope you have beautiful celebrations, and a wonderful year, Nancy!!! Sending much love - from your ENTIRE SPOHNC family!

Gifts Have Been Received In Honor Of

All Living with Head and Neck Cancer by Leone Locke

Barbara Arienti by Christina Young

Larry Baldwin by Bob Baldwin

Lewis Beilman II by Lewis J. Beilman III, Adele Bitowft

Mr. & Mrs. David Bernstein by Alfred & Susan Carfora

Richard J. Bowman by Richard Bowman

Michael Brown by Melissa Tolson

Jerry Bryant by Jerry Bryant

Mr. & Mrs. John Couri by Alfred & Susan Carfora

Steven Donahue by Mary Donahue

Butch Eaton by Sarah Williams

Dr. Joanne Fishman by Arlene Orenstein

Maria Folchetti by Angelo Aquilino

Barbara Geller by Alfred & Susan Carfora

Gale Gildow by John Gildow

Robert Harben by Herbert Hummel

Craig Hoppe by Mark Wentz

Sandra Knipe by John & Rita Lamont

Nancy Leupold by Dr. & Mrs. Eugene Myers

Cecelia Luna by Francesca Luna

Sherri Neeley by Cynthia Hanks

Joseph E. Parisi by Joseph Parisi

The Pepler Family by John Quealy

Joseph Prete by Marie Prete

Sean M. Provencher by Leone Locke

Carl Reimerdes by Alfred & Susan Carfora

Sharon Renkes by Richard Hamel

Hannelore Ring by Eric Ring

Mr. & Mrs. George Saire by Mr. & Mrs. Brindle

Garrett Smetana by Mr. & Mrs. James Gavigan

Scott Stone by Adriana Gomez

Dr. Elliot W. Strong by Eileen Sini-Gormley

Brett Thornsberry by Alison Tomecko

Debbie Weber by Norco Civic Association

Scott Weiskamp & the 2018 Animal Run by Kent Thompson

Paul Welch by Nancy Duke

Laurie Wennerholm by Steven Stern
Rick Agee’s Loving Page of Remembrance
Gifts Have Been Given In Memory Of

Wendy Abbott by Gail Fass
Rick Agee by Lynn Erickson, Steve Tauber, Martha Trubey
Vince Angelo by Nancy Nye
Trisha Adamski Appelhans by Daniel Mouch
Harold Aptaker by Ruth Aptaker
Paul Bauer by Judy Thompson
Chuck Bernard by Mary Kay Bernard
George F. Bohley, Jr. by Jane Bohley
Maria Boland by Edward Boland, Mary Ford
Doug Brino by Lewis & Amy Beilman
Richard Broome by Hershey Penn
James Richard Butterfield by Sandra Knipe
Sal Caputo by Lisa Drance
Elena Cuomo by Linda Swalling
David Davis by Emilia Read
Marc Devane by Gregory Doll, Cynthia Paraday
James Donelan by Andrea Donelan
Rebecca Vivian Fishman by Joanne Fishman
Ellen Foss by Amber Wood
Gloria Gelineau by Frederick Insogna, Anne Kinney
Harvey Gendreau
by Charles Colarullo, Cara Florio, Bruce Gregory, Marsha Martin
Scott Genova by Edward Lawrence
Frank Gormley by Eileen Sini-Gormley
Cynthia Green by Iris Trotman
Janet Greenspan by Lisa Lachs
Alice Grossman by Gary Friedman
Linda Hanlin by George Hanlin
Robert Harben by Herbert Hummel
Mary Havings by Ben Kimbler
Steven Holloway by Sharon Evans
James Huser by Linda Slack
Mario Iacona by Linda Swalling
John E. Jackson IV
David Kabat
by Laura Boyle, Ann Eiden, Douglas Engledow, Ted Gibbs
Dr. William Keane by Carol Keane
Robert Klauber by Alfred Tuckman
Felix Kleinman by Mark Kleinman
Barry Landers by Bruce & Lynn Blatt
David Lehman by Donald Roufs, Michael Sevig
Monica Levine by Michael Levine
James J. Lewis, DDS by Tanya Lewis
Sandy Litch by Philip Litch
Mary Elizabeth Loeser by Chuck Loeser
Rose and Sidney Mann by Howard Mann
Brian J. Mayer by Delrose Koch, Susan Mayer
Cody McDonald by Vicki McDonald
Robert McGeachie by Catherine McGeachie
Greg McLelland by Janet McLelland
Martha A. Miller by Edward Miller
Paul Mintautas
by Christina Barabolak, Giedre Balcuniene, Zita Baltramonas, Luc Bernard, Robert Caro, The Cuomo Family, Ruta Galinaitiis, Elizabeth Hannaway, Jane Hsiao, Steven Ito, Monte Koerner, Christine Krahulik, Virginia Maciulis, Lydia Milne, Catherine Mintautas, Karen Schmitz, Kaori Tabion, Liliana Velez, Carolyn Wornia
Ron Muller by Judy Martin
Micki Naimoli by Ben Naimoli
Dorothy Necker by Gary Friedman
Roger Nelson by Paul Hough
Michael P. Nicklos by Teri Nicklos
Evan Niizawa by Carey Tokirio
Colleen Olden by Lewis & Amy Beilman
Steven Oliva by Mary Oliva
Lois Reed by Lewis & Amy Beilman
Sherry Seitz by Margaret Seitz
Mark Shemansky
by Jennifer Barrer, Lynette Barrett, Robert Beall, Jane Bondar, Matilde Garza, Marlene Gerarge, Joseph Hammond, Annmarie Holland, Bernadette Klimes, James Russian, Mr. & Mrs. Severn, Sheila Shaffer, Mr. & Mrs. Verdict
Neil Shuster by Dale Morganstern
David Silver by Shelly DeVries, Jeff Weiner
Ronald L. Smith by Nancy Monroe Clifford
Robert L. Stanford by Mollie Stanford
Oneida Stowe by Lee Dravidzius
Sheryl Strear by Mitchell Strear
Those who have passed from this cancer in 2018 by Annette Dippolito
John Torres by Elena Torres
Barton Vest by Paul Jung
Jeannie Walsh by Andrew Erman
Madelyn Harper Walsh by Bill Walsh
William Wesp
by Romney Bathurst, Bob Campbell, Keith Clark & June Darmofal, Steven Hartman, Tone and Nancy Kwas, Dr. & Mrs. William Leahy, Bradford Lovette, Fernando Moreno, Celeste Morin, Judith Pesin, Mr. & Mrs. Saraceni, Mr. & Mrs. John Stahl, Alice Steiner, Hans Ulrich, George Vollmuth, Dennis Witmer
Tamra Sue Hamm Williams by Sue Hamm
Dorothy Winberry by Jean Menchen
Ronald Wright by Catherine Wright
your mother, Joanne by Denise Anello
your dad, Michele Ascioti by Maria Bonavita
On a cold evening in March 2015, I fussed over preparations for the first meeting of the Ann Arbor chapter of SPOHNC. I had a sign-in sheet, blank name tags, educational materials from SPOHNC to share, and even some bottles of Ensure on ice! As a Radiation Oncology social worker, I had seen a great need for a group specific to Head & Neck Cancer patients. I reached out to patient Ron and his spouse/caregiver Joanne for their advice, and to SPOHNC for their support. I sent letters of invitation to all our Head & Neck Cancer patients from the previous two years, but was still concerned about whether this was something our patients wanted. As it turned out four couples participated in that first meeting, and four years later they still attend. It has been gratifying to see the group grow in size over the years.

Our group meets for 1 1/2 hours one evening a month. The first half hour is usually devoted to a guest speaker or a special topic, after which we have open discussion. Our speakers have included Radiation Oncologists, a Medical Oncologist, a Surgeon, our Director of Research, a Dentist, an insurance verifier, and a Physical Therapist. Popular repeat guests include a Speech Therapist, a Nutritionist, and a Chaplain. Special topics have included Advance Directives, depression, and fear of recurrence.

“I don’t know why more people don’t join, because they’d gain so much,” member Don M. regularly observes. “I can’t absorb all the information from the doctors; I learn at group.” Most patients and families have experienced the information overload at the time of diagnosis and beginning of treatment. At group we slow down the news feed, allowing everyone to better understand important information. Members may even advise someone new to take notes.

Speakers have taught us exercises to help stretch neck and jaw muscles, to enhance recovery and prevent future problems such as Trismus. Such preventive measures are necessary since radiation therapy is “the gift that keeps on giving;” as caregiver Heather R. and other members note. We learn about recipes to help maintain nutritional status, and products to combat dry mouth. Each stage of the cancer journey is challenging, but for those with Oral, Head, & Neck Cancers survivorship continues to be so because of these long-term side effects. “There’s something about being with a whole group of people who have gone through the same thing,” caregiver Pat M. states.

Group member Matt R. somehow found the strength to ride his bike to most treatments, which amazed his wife Heather and other members. Caregiver Heather R. has been compiling an account of their cancer journey. Heather writes, “Our first group meeting turned out to be one of the best things we’ve ever done. Not only did we learn new information, but Matt found true camaraderie with his fellow members as did I with the caregivers…. I saw Matt come out of his shell as never before. This emboldened me to share things that I couldn’t even share with our families.” Heather concludes, “All in all the best way to articulate how we feel is simple: group has expanded our family.”

“Group opened the door for me to get through treatment,” Jim M. tells us. Each patient and caregiver have had their own adjustments to make, but Jim’s words resonate with everyone. “We’ve been very open in group – I didn’t feel alone,” Robin B. comments. Don and Pat M. mention how they “look forward to it every month.” “Group gives you power – connectivity that gets you through – bridging that gap, getting people to understand,” Rob M. relates. He also mentions how attending group gives him “insight and perspective.”

Our group welcomes caregivers and we believe they are essential to our success. I feel strongly that caregivers’ needs are also important. It is gratifying when a caregiver attends even if the patient is unable, which has happened several times. Another oncology professional who attends our meetings is Head & Neck Nurse Navigator Deb Young, RN. Deb points out that group members have had a pivotal role over the years in improving our hospital’s Head & Neck Cancer program, by bringing issues to our attention and giving us the opportunity to make improvements. In this way, they have a direct influence on the care of future patients.

Original members Hope B. and caregiver Sean B. thought they “weren’t really the support group type.” They left the first meeting, however, anticipating the next. Hope writes, “It helped me to realize I was not alone in what I was feeling physically and mentally. It helped Sean to understand he was not ‘helpless’ and that he was making a difference. Group has taught us everyone reacts differently to the treatments and that there is no right or wrong way to do things.” Hope explains why they continue to come to group: “we go so we can celebrate the progress others make…share information…finally, we continue to go as it reminds us of how far we’ve come. We have a unique group, one that I will always be grateful for.”

Our group has lost two members to cancer. We will not forget them and the time we spent together. Members have shared setbacks and been supported through them, perhaps encouraged to go back to their physician regarding a problem. But we are also able to laugh about a member choosing to drink cheap beer because he can’t taste it anyway. “The humor is very remarkable and healing,” caregiver Nancy M. rightly observes. Each month as group members arrive early and linger afterward, they share hugs and handshakes, phone numbers and photos of grandchildren. As original member/caregiver Joanne H. concludes, “It’s absolutely like a family.”

“In everyone’s life, at some time, our inner fire goes out. It is then burst into flame by an encounter with another human being. We should all be thankful for those people who rekindle the inner spirit.”

~ Albert Schweitzer
# CHAPTERS OF SPOHNC

(125+ and growing!)

Contact SPOHNC at 1-800-377-0928 for Chapter information & Facilitator contact information

<table>
<thead>
<tr>
<th>ALABAMA</th>
<th>IOWA</th>
<th>NORTH CAROLINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIRMINGHAM, HUNTSVILLE, MOBILE</td>
<td>DES MOINES</td>
<td>DURHAM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARIZONA</th>
<th>KANSAS</th>
<th>OHIO</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHANDLER, GILBERT</td>
<td>KANSAS CITY</td>
<td>CINCINNATI, CLEVELAND, DAYTON</td>
</tr>
<tr>
<td>PHOENIX (2), SCOTTSDALE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARKANSAS</th>
<th>LOUISIANA</th>
<th>OREGON</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAYETTEVILLE</td>
<td>BATON ROUGE, NEW ORLEANS</td>
<td>MEDFORD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CALIFORNIA</th>
<th>MARYLAND</th>
<th>PENNSYLVANIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>BERMLEY, NEWPORT BEACH, ORANGE-UCI, SAN DIEGO, SOUTH SAN FRANCISCO, SANTA MARIA, STANFORD, VENTURA</td>
<td>BALTIMORE-GBMC, BALTIMORE-JHMI, LIBERTY TOWN</td>
<td>DUNMORE, HERSHEY, LANCASTER, PHILADELPHIA/UNIV. PENN HOSPITAL, YORK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COLORADO</th>
<th>MISSOURI</th>
<th>SOUTH CAROLINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLORADO SPRINGS, DENVER, WHEAT RIDGE</td>
<td>ANN ARBOR, SAGINAW, WARREN</td>
<td>GREENVILLE (UPSTATE)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DC</th>
<th>MISSISSIPPI</th>
<th>TENNESSEE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEORGETOWN</td>
<td>BOSTON, CAPE COD, DANVERS</td>
<td>NASHVILLE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLORIDA</th>
<th>MISSOURI</th>
<th>TEXAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEERFIELD BEACH, FT MYERS, JACKSONVILLE (2), NAPLES, PALM COAST/NORTHEAST, WINTER PARK</td>
<td>ST. LOUIS/DPCC</td>
<td>AUSTIN, DALLAS/BICMC, DALLAS/NCC, DALLAS/UTS, FORT WORTH, SAN ANTONIO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GEORGIA</th>
<th>MISSOURI</th>
<th>VIRGINIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATLANTA, SAVALIANA</td>
<td></td>
<td>CHARLOTTESVILLE, FAIRFAX, NORFOLK, MECHANICSVILLE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IDAHO</th>
<th>MONTANA</th>
<th>WASHINGTON</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOSCOW</td>
<td>MISSOULA</td>
<td>KIRKLAND</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ILLINOIS</th>
<th>NEW JERSEY</th>
<th>WISCONSIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVANSTON, MAYWOOD, MORRIS, SPRINGFIELD</td>
<td>CAMDEN, ENGLEWOOD, LONG BRANCH, PRINCETON/UMC,</td>
<td>APPLETON</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDIANA</th>
<th>NEW YORK</th>
<th>WISCONSIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVON, SOUTH BEND, TERRE HAUTE</td>
<td>BUFFALO, MANHATTAN/BI, MANHATTAN/MS, MANHATTAN/ NYU, MIDDLETOWN, NEW HYDE PARK, ROCHESTER, STONY BROOK, SYOSSET, WHITE PLAINS</td>
<td></td>
</tr>
</tbody>
</table>
SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER (SPOHNC)

ANNUAL MEMBERSHIP

- $30.00
- $35.00 Foreign (US Currency)

CONTRIBUTIONS

- Booster, $35+
- Donor, $50+
- Sponsor, $100+
- Patron, $500+
- Benefactor, $1,000+
- Founder, $5,000+
- Leaders Circle, $10,000+
- Visionary Circle $15,000+

Call 1-800-377-0928 to become a member and make a contribution by credit card or order online at www.spohnc.org

MEMBERSHIP APPLICATION

SUPPORT FOR PEOPLE WITH ORAL AND HEAD AND NECK CANCER, INC.
P.O. Box 53, Locust Valley, NY 11560

Membership includes subscription to eight issues of News From SPOHNC & FREE Product Directory

Name______________________________________________________________
Phone (________)__________________________
Address_________________________________________________
Email Address________________________________________
Address____________________________________________________________________________________________________
City_________________________________________State________________Zip________________________
Please Check:   Survivor ____Friend  ____Health Professional (Specialty)  _______________________________________________
First time member__________  Returning member________

TOGETHER WE HEAL

Give a gift to SPOHNC today
For your convenience your appeal envelope is enclosed.